PAC-1

DRUG2 trials

Sponsors

Vanquish Oncology, Inc., Arkadiusz Z. Dudek, MD

Conditions

Neuroendocrine TumorsPancreatic Neuroendocrine TumorSolid TumorUveal Melanoma

Phase 1

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

CompletedNCT02355535

Vanquish Oncology, Inc.Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Solid Tumor

Start: 2015-02-28End: 2020-05-18Updated: 2020-09-24

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

TerminatedNCT04589832

Arkadiusz Z. Dudek, MDUveal Melanoma

Start: 2021-01-11End: 2022-06-24Updated: 2023-11-22

Related Papers

Abstract LB075: Small molecule procaspase activating compound 1 (PAC-1) enhances CAR-T immunotherapy for solid tumors in syngeneic murine models

Cancer Research2024-04-05

The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma

Melanoma Research2023-09-227 citations

Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies.

2022-12-0524 citations

Abstract LB-330: Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies

Cancer Research2020-08-15

Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.

Journal of Clinical Oncology2019-05-20

Phase I study of procaspase activating compound-1 (PAC-1) for treatment of advanced malignancies.

Journal of Clinical Oncology2018-05-203 citations

Phase I study of procaspase activating compound -1 (PAC-1) in the treatment of advanced malignancies.

Journal of Clinical Oncology2016-05-207 citations

Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities

Current Medicinal Chemistry2016-01-2241 citations

Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies.

Journal of Clinical Oncology2015-05-201 citations

Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics

Journal of Medicinal Chemistry2015-04-0925 citations